Poolbeg Pharma PLC
Research Poolbeg Pharma PLC (POLB) on Bullrun: market cap GBX 4.72B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPOLB
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 4.72B
- Financial periodFY2024
- Net income-GBP 5.79M
- Free cash flow-GBP 4.78M
Valuation Snapshot
latest market cap is GBX 4.72B.
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses.
Frequently asked questions
What is Poolbeg Pharma PLC's market cap?
Poolbeg Pharma PLC's market capitalization is GBX 4.72B.
What does Poolbeg Pharma PLC do?
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome;